Keymed Biosciences Inc. (HKG:2162)

Market Cap	17.41B
Revenue (ttm)	955.73M
Net Income (ttm)	-281.99M
Shares Out	294.60M
EPS (ttm)	-1.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,193,827
Average Volume	1,639,705
Open	59.20
Previous Close	58.95
Day's Range	58.35 - 60.05
52-Week Range	27.05 - 80.00
Beta	-0.05
RSI	46.15
Earnings Date	Nov 26, 2025

About Keymed Biosciences

Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China and internationally. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), chronic rhinosinusitis with nasal polyposis (CRSwNP), seasonal allergic rhinitis, prurigo nodularis, and respiratory related indications. The company is also developing CMG901, a Claudin 18.2 antibody drug conjugate in Phase III trial to treat gas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 1,258
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2162

Financial Performance

In 2024, Keymed Biosciences's revenue was 428.12 million, an increase of 20.91% compared to the previous year's 354.10 million. Losses were -515.24 million, 43.4% more than in 2023.

Financial numbers in CNY